- Home
- ANAB vs ITRN Comparison
ANAB vs ITRN Comparison
Compare ANAB & ITRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ITRN
- Stock Information
- Founded
- ANAB 2005
- ITRN 1994
- Country
- ANAB United States
- ITRN Israel
- Employees
- ANAB N/A
- ITRN N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ITRN Electronic Components
- Sector
- ANAB Health Care
- ITRN Technology
- Exchange
- ANAB Nasdaq
- ITRN Nasdaq
- Market Cap
- ANAB 600.4M
- ITRN 533.5M
- IPO Year
- ANAB 2017
- ITRN 2005
- Fundamental
- Price
- ANAB $22.27
- ITRN $28.98
- Analyst Decision
- ANAB Buy
- ITRN
- Analyst Count
- ANAB 11
- ITRN 0
- Target Price
- ANAB $54.64
- ITRN N/A
- AVG Volume (30 Days)
- ANAB 623.5K
- ITRN 61.5K
- Earning Date
- ANAB 11-05-2024
- ITRN 11-21-2024
- Dividend Yield
- ANAB N/A
- ITRN 5.38%
- EPS Growth
- ANAB N/A
- ITRN 15.21
- EPS
- ANAB N/A
- ITRN 2.61
- Revenue
- ANAB $57,172,000.00
- ITRN $331,182,000.00
- Revenue This Year
- ANAB $207.49
- ITRN $8.67
- Revenue Next Year
- ANAB N/A
- ITRN $10.47
- P/E Ratio
- ANAB N/A
- ITRN $11.10
- Revenue Growth
- ANAB 282.17
- ITRN 4.43
- 52 Week Low
- ANAB $13.36
- ITRN $24.12
- 52 Week High
- ANAB $41.31
- ITRN $30.00
- Technical
- Relative Strength Index (RSI)
- ANAB 42.41
- ITRN 67.68
- Support Level
- ANAB $18.03
- ITRN $26.50
- Resistance Level
- ANAB $22.94
- ITRN $29.47
- Average True Range (ATR)
- ANAB 1.37
- ITRN 0.63
- MACD
- ANAB 0.45
- ITRN 0.12
- Stochastic Oscillator
- ANAB 86.18
- ITRN 83.56
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ITRN Ituran Location and Control Ltd.
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services, and Telematics products. The Telematics services segment consists of regionally- based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal advanced locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location, and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others.